197 related articles for article (PubMed ID: 37925511)
1. Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy.
Taborska P; Lukac P; Stakheev D; Rajsiglova L; Kalkusova K; Strnadova K; Lacina L; Dvorankova B; Novotny J; Kolar M; Vrana M; Cechova H; Ransdorfova S; Valerianova M; Smetana K; Vannucci L; Smrz D
Sci Rep; 2023 Nov; 13(1):19079. PubMed ID: 37925511
[TBL] [Abstract][Full Text] [Related]
2. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of NCC-UPS3-C1: a novel patient-derived cell line of undifferentiated pleomorphic sarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Akiyama T; Sugaya J; Nakatani F; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2022 Jan; 35(1):384-391. PubMed ID: 34665443
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
[TBL] [Abstract][Full Text] [Related]
5. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
6. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
Lee K; Song JS; Kim JE; Kim W; Song SY; Lee MH; Chung HW; Cho KJ; Lee JS; Ahn JH
Eur J Surg Oncol; 2020 Jul; 46(7):1287-1293. PubMed ID: 32127249
[TBL] [Abstract][Full Text] [Related]
7. Status of programmed death-ligand 1 expression in sarcomas.
Park HK; Kim M; Sung M; Lee SE; Kim YJ; Choi YL
J Transl Med; 2018 Nov; 16(1):303. PubMed ID: 30400799
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.
Rangan L; Galaine J; Boidot R; Hamieh M; Dosset M; Francoual J; Beziaud L; Pallandre JR; Lauret Marie Joseph E; Asgarova A; Borg C; Al Saati T; Godet Y; Latouche JB; Valmary-Degano S; Adotévi O
Oncotarget; 2017 Jul; 8(30):48959-48971. PubMed ID: 28430664
[TBL] [Abstract][Full Text] [Related]
10. Detection of Metastasis in a Patient-derived Orthotopic Xenograft (PDOX) Model of Undifferentiated Pleomorphic Sarcoma with Red Fluorescent Protein.
Oshiro H; Kiyuna T; Tome Y; Miyake K; Kawaguchi K; Higuchi T; Miyake M; Zhang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Nelson SD; Li Y; Bouvet M; Singh SR; Kanaya F; Hoffman RM
Anticancer Res; 2019 Jan; 39(1):81-85. PubMed ID: 30591443
[TBL] [Abstract][Full Text] [Related]
11. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
12. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases.
Vodanovich DA; Spelman T; May D; Slavin J; Choong PFM
ANZ J Surg; 2019 Sep; 89(9):1045-1050. PubMed ID: 31364245
[TBL] [Abstract][Full Text] [Related]
13. A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma.
Graves L; Jeck WR; Grilley-Olson JE
Curr Treat Options Oncol; 2023 Mar; 24(3):212-228. PubMed ID: 36729198
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome.
Ono T; Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Akiyama T; Sugaya J; Fukushima S; Kojima N; Yoshida A; Kawai A; Kondo T
Hum Cell; 2022 Mar; 35(2):756-766. PubMed ID: 35118583
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
[TBL] [Abstract][Full Text] [Related]
17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
18. Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures.
Cheung LS; Chen L; Oke TF; Schaffer TB; Boudadi K; Ngo JT; Gross JM; Kemberling H; Diaz LA; Lipson E; Sidhom JW; Taube J; Anders R; Pardoll DM; Le DT; Meyer CF; Llosa N
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103354
[TBL] [Abstract][Full Text] [Related]
19. Undifferentiated Pleomorphic Sarcoma of a Chronic Burn Scar of the Knee With Lymph Node Metastasis.
Choi JY; Cha WJ; Kim J; Jung ER; Jung SN; Seo BF
Int J Low Extrem Wounds; 2023 Dec; 22(4):767-773. PubMed ID: 34791920
[TBL] [Abstract][Full Text] [Related]
20. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
